[1] 魏艳艳, 李文学, 张威. 氯氮平与利培酮对首发精神分裂症病人糖脂代谢的影响[J]. 临床医学, 2018, 38(12): 101.
[2] 钱秀莲, 徐裕, 陈云郁. 三种抗精神类药物治疗首发精神分裂症病人的疗效比较[J]. 现代实用医学, 2017, 29(11): 1459. doi: 10.3969/j.issn.1671-0800.2017.11.028
[3] 骆祥芬, 储辉, 王升, 等. 伴迟发性运动障碍的慢性精神分裂症病人认知功能状况分析[J]. 蚌埠医学院学报, 2020, 45(2): 255. doi: 10.13898/j.cnki.issn.1000-2200.2020.02.033
[4] 刘宏明, 王建, 陈盛阳. MCT配合齐拉西酮治疗SCH效果及对认知功能的影响[J]. 西南国防医药, 2020, 30(2): 141. doi: 10.3969/j.issn.1004-0188.2020.02.017
[5] 王朔, 江涛, 余燕萍. 氯氮平对精神分裂症病人骨密度、睾酮、泌乳素及骨质疏松的影响[J]. 中国现代医学杂志, 2020, 30(19): 78.
[6] KAHN RS, ROSSUM IW, LEUCHT S, et al. Amisulpride and olanzapine followed by open-label treatment with clozapine in first-episode schizophrenia and schizophreniform disorder (OPTiMiSE): a three-phase switching study[J]. Lancet Psychiatry, 2018, 5(10): 797. doi: 10.1016/S2215-0366(18)30252-9
[7] 管欣, 刘强, 唐文熙, 等. 基于决策树模型对我国5种常用非典型抗精神病药一线治疗首发精神分裂症的成本效果分析[J]. 中国新药杂志, 2017, 10(17): 121.
[8] HOU YY, XIE JH, YUAN YB, et al. Neurocognitive effects of atypical antipsychotics in patients with first-episode schizophrenia[J]. Nord J Psychiatry, 2020, 74(8): 594. doi: 10.1080/08039488.2020.1771767
[9] FRANBERG O, MARCUS MM, SVENSSON TH. Involvement of 5-HT2A receptor and alpha2-adrenoceptor blockade in the asenapine-induced elevation of prefrontal cortical monoamine outflow[J]. Synapse, 2012, 66(7): 650.
[10] KUO HI, PAULUS W, BATSIKADZE G, et al. Acute and chronic effects of noradrenergic enhancement on transcranial direct current stimulation (tDCS)-induced neuroplasticity in humans[J]. J Physiol, 2017, 595(4): 1305.
[11] TAKEKITA Y, KOSHIKAWA Y, FABBRI C, et al. Cognitive function and risperidone longacting injection vs. paliperidone palmitate in schizophrenia: a 6-month, open-label, randomized, pilot trial[J]. BMC Psychiatry, 2016, 16: 172.
[12] KRAKOWSKI M, CZOBOR P. Cholesterol and cognition in schizophrenia: a double-blind study of patients randomized to clozapine, olanzapine and haloperidol[J]. Schizophr Res, 2011, 130(1/3): 27.
[13] 黄磊, 钱建军, 田国强, 等. 不同药物联合利培酮及认知行为治疗残留型精神分裂症的疗效分析[J]. 中华全科医学, 2016, 14(11): 1816.
[14] FAN XD, COPELAND P, NAWRAS S, et al. Adjunctive telmisartan treatment on body metabolism in clozapine or olanzapine treated patients with schizophrenia: a randomized, double blind, placebo controlled trial[J]. Psychopharmacology (Berl), 2019, 236(6): 1949.
[15] MAAGENSEN H, LARSEN JR, JØRGENSEN NR, et al. Liraglutide does not change bone turnover in clozapine- and olanzapine-treated schizophrenia overweight patients with prediabetes-randomized controlled trial[J]. Psychiatry Res, 2021, 296: 113670.
[16] HE SD, YU WJ, WANG XL, et al. Risk factors of hyperprolactinemia induced by risperidone and olanzapine and their correlations with plasma glucose and lipids[J]. Gen Psychiatr, 2020, 33(4): e100206.
[17] 陈红磊, 周琳, 郭传连, 等. 阿立哌唑、氯氮平、利培酮三种抗精神病药物对精神分裂症病人泌乳素及雌二醇的影响观察[J]. 临床研究, 2019, 27(12): 145.
[18] 李浩军, 景兰, 孟根花. 4种抗精神病药物对精神分裂症病人制糖代谢及血清催乳素水平的影响[J]. 中国医师杂志, 2020, 22(8): 1255.
[19] 莫亚莉, 夏泳, 金曼, 等. 无抽搐电休克治疗对精神分裂症病人自传体记忆及疗效的影响[J]. 中华行为医学与脑科学杂志, 2019, 28(3): 250.
[20] 林春燕, 周红蕊, 黎顺成, 等. 探讨奥氮平对首发精神分裂症伴肥胖病人认知功能、糖脂代谢及相关激素指标水平的影响[J]. 中国医院药学杂志, 2019, 38(9): 239.